Search Results - Aggrey Bukuru

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group

    Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerab... by Lalloo, Umesh G, Komarow, Lauren, Aberg, Judith A, Clifford, David B, Hogg, Evelyn, McKhann, Ashley, Bukuru, Aggrey, Lagat, David, Pillay, Sandy, Mave, Vidya, Supparatpinyo, Khuanchai, Samaneka, Wadzanai, Langat, Deborah, Ticona, Eduardo, Badal-Faesen, Sharlaa, Larsen, Robert A

    Published in PloS one
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial

    Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 wee... by Avihingsanon, Anchalee, Hughes, Michael D., Salata, Robert, Godfrey, Catherine, McCarthy, Caitlyn, Mugyenyi, Peter, Hogg, Evelyn, Gross, Robert, Cardoso, Sandra W., Bukuru, Aggrey, Makanga, Mumbi, Badal‐aesen, Sharlaa, Mave, Vidya, Ndege, Beatrice Wangari, Fontain, Sandy Nerette, Samaneka, Wadzanai, Secours, Rode, Van Schalkwyk, Marije, Mngqibisa, Rosie, Mohapi, Lerato, Valencia, Javier, Sugandhavesa, Patcharaphan, Montalban, Esmelda, Munyanga, Cornelius, Chagomerana, Maganizo, Santos, Breno R., Kumarasamy, Nagalingeswaran, Kanyama, Cecilia, Schooley, Robert T., Mellors, John W., Wallis, Carole L., Collier, Ann C., Grinsztejn, Beatriz

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis

    Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis by Lalloo, Umesh G, Komarow, Lauren, Aberg, Judith A, Clifford, David B, Hogg, Evelyn, McKhann, Ashley, Bukuru, Aggrey, Lagat, David, Pillay, Sandy, Mave, Vidya, Supparatpinyo, Khuanchai, Samaneka, Wadzanai, Langat, Deborah, Ticona, Eduardo, Badal-Faesen, Sharlaa, Larsen, Robert A

    Published in PloS one
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial

    As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC... by Hosseinipour, Mina C, Kang, Minhee, Krown, Susan E, Bukuru, Aggrey, Umbleja, Triin, Martin, Jeffrey N, Orem, Jackson, Godfrey, Catherine, Hoagland, Brenda, Mwelase, Noluthando, Langat, Deborah, Nyirenda, Mulinda, MacRae, John, Borok, Margaret, Samaneka, Wadzanai, Moses, Agnes, Mngqbisa, Rosie, Busakhala, Naftali, Martínez-Maza, Otoniel, Ambinder, Richard, Dittmer, Dirk P, Nokta, Mostafa, Campbell, Thomas B

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group

    Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerab... by Umesh G Lalloo, Lauren Komarow, Judith A Aberg, David B Clifford, Evelyn Hogg, Ashley McKhann, Aggrey Bukuru, David Lagat, Sandy Pillay, Vidya Mave, Khuanchai Supparatpinyo, Wadzanai Samaneka, Deborah Langat, Eduardo Ticona, Sharlaa Badal-Faesen, Robert A Larsen, ACTG A5225 Team

    Published in PloS one
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Third‐line antiretroviral therapy, including raltegravir , is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial

    Third‐line antiretroviral therapy, including raltegravir , is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 stra... by Avihingsanon, Anchalee, Hughes, Michael D, Salata, Robert, Godfrey, Catherine, Mccarthy, Caitlyn, Mugyenyi, Peter, Hogg, Evelyn, Gross, Robert, Cardoso, Sandra W, Bukuru, Aggrey, Makanga, Mumbi, Badal?Aesen, Sharlaa, Mave, Vidya, Ndege, Beatrice Wangari, Fontain, Sandy Nerette, Samaneka, Wadzanai, Secours, Rode, Van Schalkwyk, Marije, Mngqibisa, Rosie, Mohapi, Lerato, Valencia, Javier, Sugandhavesa, Patcharaphan, Montalban, Esmelda, Munyanga, Cornelius, Chagomerana, Maganizo, Santos, Breno R, Kumarasamy, Nagalingeswaran, Kanyama, Cecilia, Schooley, Robert T, Mellors, John W, Wallis, Carole L, Collier, Ann C, Grinsztejn, Beatriz

    Get full text
    Article
    Save to List
    Saved in:

Search Tools: